Human Type 3 3α-Hydroxysteroid Dehydrogenase (Aldo-Keto Reductase 1C2) and Androgen Metabolism in Prostate Cells
The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Abstract
Human aldo-keto reductases (AKRs) of the AKR1C subfamily function in vitro as 3-keto-, 17-keto-, and 20-ketosteroid reductases or as 3α-, 17β-, and 20α-hydroxysteroid oxidases. These AKRs can convert potent sex hormones (androgens, estrogens, and progestins) into their cognate inactive metabolites or vice versa. By controlling local ligand concentration AKRs may regulate steroid hormone action at the prereceptor level. AKR1C2 is expressed in prostate, and in vitro it will catalyze the nicotinamide adenine dinucleotide (NAD+)-dependent oxidation of 3α-androstanediol (3α-diol) to 5α-dihydrotestosterone (5α-DHT). This reaction is potently inhibited by reduced NAD phosphate (NADPH), indicating that the NAD+: NADPH ratio in cells will determine whether AKR1C2 makes 5α-DHT. In transient COS-1-AKR1C2 and in stable PC-3-AKR1C2 transfectants, 5α-DHT was reduced by AKR1C2. However, the transfected AKR1C2 oxidase activity was insufficient to surmount the endogenous 17β-hydroxysteroid dehydrogenase (17β-HSD) activity, which eliminated 3α-diol as androsterone. PC-3 cells expressed retinol dehydrogenase/3α-HSD and 11-cis-retinol dehydrogenase, but these endogenous enzymes did not oxidize 3α-diol to 5α-DHT. In stable LNCaP-AKR1C2 transfectants, AKR1C2 did not alter androgen metabolism due to a high rate of glucuronidation. In primary cultures of epithelial cells, high levels of AKR1C2 transcripts were detected in prostate cancer, but not in cells from normal prostate. Thus, in prostate cells AKR1C2 acts as a 3-ketosteroid reductase to eliminate 5α-DHT and prevents activation of the androgen receptor. AKR1C2 does not act as an oxidase due to either potent product inhibition by NADPH or because it cannot surmount the oxidative 17β-HSD present. Neither AKR1C2, retinol dehydrogenase/3α-HSD nor 11-cis-retinol dehydrogenase is a source of 5α-DHT in PC-3 cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These enzymes preferably act as reductases in vivo since they have Kd values for NADPH in the nanomolar range, there is a high NADPH/NADP+ ratio within cells and NADPH inhibits the NAD+ dependent oxidation reactions at low μM concentrations”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“In peripheral tissues, AKR1C enzymes act as 3-keto and 17-ketosteroid reductases to catalyze either the formation of the most potent androgen 5α-dihydrotestosterone (5α-DHT) or its inactivation to yield the inactive androgens 5α-androstane-3α,17β-diol (3α-Diol) or 5α-androstane-3β,17β-diol (3β-Diol)”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“COS-1, PC-3 and LNCaP cells transfected with AKR1C2 were able to recapitulate this reaction”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“AKR1C2 has the highest catalytic efficiency as a 3-ketosteroid reductase and catalyzes reduction of 5α-DHT to 3α-Diol”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“AKR1C3 catalyzes the reduction of Δ4-androstene-3,17-dione to form the potent androgen testosterone (Kd = 10−9 M for AR) and the reduction of 5α-androstane-3,17-dione to yield the most potent androgen 5α-DHT (Kd =10−10 M for the AR).”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105
PENNING, T. M., BURCZYNSKI, M. E., JEZ, J. M., HUNG, C.-F., LIN, H.-K., MA, H., MOORE, M., PALACKAL, N., & RATNAM, K. (2000) · Biochemical Journal · doi:10.1042/bj3510067 · Cited by 649
Self-citationThe induction of prostatic hypertrophy in the dog with androstanediol.
Walsh, P. C., & Wilson, J. D. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108353 · Cited by 418
A new nomenclature for the aldo-keto reductase superfamily
Jez, J. M., Flynn, T. G., & Penning, T. M. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)84253-0 · Cited by 354
Self-citationThe clinical development of a 5α-reductase inhibitor, finasteride
Stoner, E. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90487-6 · Cited by 224
Biswas, M. G., & Russell, D. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.25.15959 · Cited by 224
Hormones and Prostate Cancer: What's Next?
Hsing, A. W. (2001) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a000795 · Cited by 216
Lin, H.-K., Jez, J. M., Schlegel, B. P., Peehl, D. M., Pachter, J. A., & Penning, T. M. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.13.0026 · Cited by 194
Self-citationThe role of androgens and the androgen receptor in prostate cancer.
Debes, J. D., & Tindall, D. J. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00413-5 · Cited by 191
Research works printed but not linked: 3
- Griffiths, 1999, Aspects of the cell biology of prostate cancer, 51
- Barbier, 2000, Cellular localization of uridine diphosphoglucronsyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistichemistry., J Clin Endocrinol Metab, 85, 4819
- Peehl, 1992, Culture of human prostate epithelial cells, 159
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
“Previous studies found that expression of AKR1C2 was decreased in primary prostate cancer relative to normal prostate, and this was proposed as a mechanism for increasing intracellular dihydrotestosterone in primary prostate cancer (53, 54).”
BackgroundSelf-citationThe aldo-keto reductases (AKRs): Overview
Penning, T. M. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.09.024 · Cited by 543
Self-citationGonadal steroid hormones and the hypothalamo–pituitary–adrenal axis
Handa, R. J., & Weiser, M. J. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.11.001 · Cited by 408
“[PubMed: 7958169] Jin Y, Penning TM. Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism.”
InfluentialAldo-Keto Reductases and Bioactivation/Detoxication
Jin, Y., & Penning, T. M. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105337 · Cited by 383
Self-citationSteckelbroeck, S., Jin, Y., Gopishetty, S., Oyesanmi, B., & Penning, T. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313308200 · Cited by 270
Self-citationHuman aldo–keto reductases: Function, gene regulation, and single nucleotide polymorphisms
Penning, T. M., & Drury, J. E. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.04.024 · Cited by 266
Self-citationFlück, C. E., Meyer-Böni, M., Pandey, A. V., Kempná, P., Miller, W. L., Schoenle, E. J., & Biason-Lauber, A. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.06.009 · Cited by 248
The Biological Actions of Dehydroepiandrosterone Involves Multiple Receptors
Webb, S. J., Geoghegan, T. E., Prough, R. A., & Michael Miller, K. K. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600569877 · Cited by 237
“This phenomenon is an example of pre-receptor processing of sterol ligands formed from DHEA by various hydroxysteroid dehydrogenases (Rizner et al., 2003).”
BackgroundLycopene: modes of action to promote prostate health
Wertz, K., Siler, U., & Goralczyk, R. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.04.023 · Cited by 229
Intracrine androgen biosynthesis, metabolism and action revisited
Schiffer, L., Arlt, W., & Storbeck, K.-H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.016 · Cited by 217
“Additionally, the back conversion of 3a-adiol to DHT by oxidative 3aHSDs has been demonstrated for prostate cancer cell lines enabling a recycling of this DHT metabolite (Bauman et al., 2006; Mohler et al., 2011; Rizner et al., 2003).”
Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism
Rižner, T. L., & Penning, T. M. (2014) · Steroids · doi:10.1016/j.steroids.2013.10.012 · Cited by 217
Self-citationMechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
Steroid hormone transforming aldo–keto reductases and cancer
Penning, T. M., & Byrns, M. C. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03700.x · Cited by 181
Self-citationMolecular mechanisms regulating glucocorticoid sensitivity and resistance
Gross, K. L., Lu, N. Z., & Cidlowski, J. A. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.10.001 · Cited by 180
“…et al., 1993; Wilson et al., 1994; Yeh et al., 1996; Nelson et al., 1999; Stewart et al., 1999; Flouriot et al., 2000; Quinkler et al., 2003; Rizner et al., 2003; Kobayashi et al., 2004; Pascual-Le Tallec et al., 2004; Lu et al., 2005; Pascual-Le Tallec et al., 2005; Chen et al., 2006;…”
Intra‐adipose sex steroid metabolism and body fat distribution in idiopathic human obesity
Wake, D. J., Strand, M., Rask, E., Westerbacka, J., Livingstone, D. E. W., Soderberg, S., Andrew, R., Yki‐Jarvinen, H., Olsson, T., & Walker, B. R. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02755.x · Cited by 179
Primary cell cultures as models of prostate cancer development
Peehl, D. M. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00795 · Cited by 173
“Cytokeratin 19, expressed by both basal and secretory cells of the prostatic epithelium, is also expressed by cultured cells (Peehl et al. 1996, Robinson et al. 1998).”
BackgroundSelf-citationRedirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Li, Z., Alyamani, M., Li, J., Rogacki, K., Abazeed, M., Upadhyay, S. K., Balk, S. P., Taplin, M.-E., Auchus, R. J., & Sharifi, N. (2016) · Nature · doi:10.1038/nature17954 · Cited by 171
Structural and functional biology of aldo-keto reductase steroid transforming enzymes
Penning, T. M., Wangtrakuldee, P., & Auchus, R. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00089 · Cited by 164
Self-citationAKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer
Rižner, T. L., Šmuc, T., Rupreht, R., Šinkovec, J., & Penning, T. M. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.10.009 · Cited by 159
Self-citationIntratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
Cai, C., & Balk, S. P. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-10-0339 · Cited by 155
“…of reducing androstenedione to testosterone, it appears to primarily reduce DHT to 5a-androstane-3a,17b-diol (3a-androstanediol; Ji et al. 2003, Rizner et al. 2003), which is then glucuronidated to form 3a-androstanediol glucuronide by the enzymes UDP glycosyltransferase 2, B15 (UGT2B15) or…”
BackgroundThe syndrome of 17,20 lyase deficiency
Miller, W. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2161 · Cited by 143
Structure–function of human 3α-hydroxysteroid dehydrogenases: genes and proteins
Penning, T. M., Jin, Y., Steckelbroeck, S., Rižner, T. L., & Lewis, M. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.11.006 · Cited by 160
Self-citationMultiple functions of type 10 17β-hydroxysteroid dehydrogenase
Yang, S., He, X., & Schulz, H. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.03.006 · Cited by 149
Fung, K.-M., Samara, E. N. S., Wong, C., Metwalli, A., Krlin, R., Bane, B., Liu, C. Z., Yang, J. T., Pitha, J. V., Culkin, D. J., et al. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01048 · Cited by 129
“This mAb is monospecific against AKR1C3 (Lin et al. 2004) and does not cross-react with AKR1C1, AKR1C2 or AKR1C4.”
ResultInfluentialSelf-citationBauman, D. R., Rudnick, S. I., Szewczuk, L. M., Jin, Y., Gopishetty, S. R., & Penning, T. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.006569 · Cited by 124
“The human AKR1C isozymes are hydroxysteroid dehydrogenases (HSDs) and are involved in the prereceptor regulation of steroid hormone action (Penning, 1997; Dufort et al., 1999; Dufort et al., 2001; Rizner et al., 2003).”
BackgroundSelf-citationAldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors
Penning, T. M., Steckelbroeck, S., Bauman, D. R., Miller, M. W., Jin, Y., Peehl, D. M., Fung, K.-M. A., & Lin, H.-K. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.12.009 · Cited by 127
Self-citationBauman, D. R., Steckelbroeck, S., Williams, M. V., Peehl, D. M., & Penning, T. M. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0287 · Cited by 120
Self-citationPenning, T. M. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.07.002 · Cited by 117
“…the NAD(H) cofactors is in the 200 μM range; (iv) low micromolar concentrations of NADPH can inhibit the reverse NAD+ dependent oxidation reactions (Rizner et al., 2003); and (v) in transfection experiments in mammalian cells, where AKR1C3 must use the prevailing NAD(P)(H) concentrations, only…”
BackgroundSelf-citationAdeniji, A. O., Twenter, B. M., Byrns, M. C., Jin, Y., Chen, M., Winkler, J. D., & Penning, T. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201547v · Cited by 119
Self-citationUnique patterns of molecular profiling between human prostate cancer LNCaP and PC‐3 cells
Dozmorov, M. G., Hurst, R. E., Culkin, D. J., Kropp, B. P., Frank, M. B., Osban, J., Penning, T. M., & Lin, H. (2009) · The Prostate · doi:10.1002/pros.20960 · Cited by 124
“Unique expression of UGT2B15 and UGT2B17 in LNCaP but not in PC-3 cells is consistent with our biochemical characterization in which androgen metabolites are rapidly glucuronidated in LNCaP, but not in PC-3 cells [40].”
ResultSelf-citationLiedtke, A. J., Adeniji, A. O., Chen, M., Byrns, M. C., Jin, Y., Christianson, D. W., Marnett, L. J., & Penning, T. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017656 · Cited by 101
Self-citationPenning, T. M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00319 · Cited by 106
Self-citationDallas, S. L., Zhao, S., Cramer, S. D., Chen, Z., Peehl, D. M., & Bonewald, L. F. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20147 · Cited by 102
“The production of high levels of active TGFb is rare among the many cell types reported (reviewed in Roberts, 1998).”
BackgroundSelf-citationSex steroid hormone metabolism and prostate cancer
Soronen, P., Laiti, M., Törn, S., Härkönen, P. K., Patrikainen, L., Li, Y., Pulkka, A. E., Kurkela, R., Herrala, A. M., Kaija, H., et al. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.10.004 · Cited by 98
Steroid hormone synthetic pathways in prostate cancer.
Mostaghel, E. A. (2013) · PubMed · doi:10.3978/j.issn.2223-4683.2013.09.16 · Cited by 80
“The reductase activity of AKR1C2, coupled with the reverse oxidative activity of specific 3α-HSD enzymes is a critical molecular switch regulating access of DHT to the AR (44-47).”
BackgroundVeliça, P., Davies, N. J., Rocha, P. P., Schrewe, H., Ride, J. P., & Bunce, C. M. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-121 · Cited by 79
“In the prostate, AKR1C2 and AKR1C3 play a key role in regulating activation of the androgen receptor (AR)[5,12, 13 ] (Fig 1). AKR1C2 inactivates the potent AR ligand 5α-dihydrotestosterone (5α-DHT) by converting it to 3α-adiol (weak AR ligand) [13,14].”
BackgroundIshizaki, F., Nishiyama, T., Kawasaki, T., Miyashiro, Y., Hara, N., Takizawa, I., Naito, M., & Takahashi, K. (2013) · Scientific Reports · doi:10.1038/srep01528 · Cited by 90
Muthusamy, S., Andersson, S., Kim, H.-J., Butler, R., Waage, L., Bergerheim, U., & Gustafsson, J.-Å. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117772108 · Cited by 72
“A candidate for the first step in the twoenzymepathway isAKR1C2, which convertsDHT to 3α-Adiol (9).”
Bauman, D. R., Steckelbroeck, S., Peehl, D. M., & Penning, T. M. (2006) · Endocrinology · doi:10.1210/en.2006-0627 · Cited by 72
Self-citationBordini, J., Morisi, F., Elia, A. R., Santambrogio, P., Pagani, A., Cucchiara, V., Ghia, P., Bellone, M., Briganti, A., Camaschella, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3182 · Cited by 80
“Bicalutamide promotes the expression of AKR1C1 and AKR1C2, members of the AKR1C superfamily of steroid hormone– transforming enzymes that under physiologic conditions act as reductases since the usual cell concentration of NAD(P)H prevents their oxidase activity (23, 29).”
BackgroundOf marsupials and men: “Backdoor” dihydrotestosterone synthesis in male sexual differentiation
Biason-Lauber, A., Miller, W. L., Pandey, A. V., & Flück, C. E. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.017 · Cited by 69
“When transfected into COS-1 cells, the available concentrations of cofactors result in AKR1C2 functioning as a reductase, but not as an oxidase (Rizner et al., 2003), and when 1 mM NAD+ is supplied to recombinant AKR1C2 in vitro to permit oxidation of 3aDiol to DHT, the reaction can be blocked by…”
InfluentialSteckelbroeck, S., Oyesanmi, B., Jin, Y., Lee, S. H., Kloosterboer, H. J., & Penning, T. M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.091587 · Cited by 68
“In human liver autopsy samples, high NADPH-dependent formation of 3 -hydroxytibolone was exclusively enriched in the cytosolic fraction (Fig.”
BackgroundSelf-citationSteckelbroeck, S., Jin, Y., Oyesanmi, B., Kloosterboer, H. J., & Penning, T. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.004515 · Cited by 64
“Previous studies using 5 -DHT and 3 -androstanediol demonstrated that, in transfected COS-1 and PC-3 cell lines, AKR1C2 worked exclusively as a 3-ketosteroid reductase (Rižner et al., 2003).”
MethodSelf-citationWang, S., Yang, Q., Fung, K.-M. A., & Lin, H. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.04.004 · Cited by 70
Self-citationHe, X., Węgiel, J., & Yang, S. (2005) · Brain Research · doi:10.1016/j.brainres.2005.01.022 · Cited by 76
Jin, Y., & Penning, T. M. (2006) · Biochemistry · doi:10.1021/bi060591r · Cited by 60
Self-citationCooper, W. C., Jin, Y., & Penning, T. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703414200 · Cited by 58
Self-citationPre-receptor regulation of the androgen receptor
Penning, T. M., Jin, Y., Rižner, T. L., & Bauman, D. R. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.10.008 · Cited by 68
“[PubMed: 2845584] Gough WH, Van Ooteghem S, Sint T, Kedishvili NY. cDNA cloning and characterization of a new human microsomal NAD+-dependent dehydrogenase that oxidizes all trans-retinol and 3α-hydroxysteroids.”
BackgroundMethodInfluentialSelf-citationHe, X., Węgiel, J., Yang, Y., Pullarkat, R. K., Schulz, H., & Yang, S. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.08.011 · Cited by 54
“E-mail address:yangsongyu@yahoo.com (S.-Y. Yang). roactive steroids rapidly modulate neuronal excitability have pronounced anxiolytic and anticonvulsant effects in (Rupprecht et al., 2001).”
New frontiers in androgen biosynthesis and metabolism
Penning, T. M. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283381a31 · Cited by 51
Self-citationControl of cell proliferation by steroids: The role of 17HSDs
Vihko, P., Herrala, A. M., Härkönen, P. K., ISOMAA, V. V., Kaija, H., Kurkela, R., & Pulkka, A. E. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.12.005 · Cited by 59
Identification of the molecular switch that regulates access of 5α-DHT to the androgen receptor
Penning, T. M., Bauman, D. R., Jin, Y., & Rižner, T. L. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.12.007 · Cited by 57
Self-citationJin, Y., Duan, L., Lee, S. H., Kloosterboer, H. J., Blair, I. A., & Penning, T. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809465200 · Cited by 50
Self-citationPenning, T. M. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.01.009 · Cited by 50
Self-citationAldo-keto reductase 1C3—Assessment as a new target for the treatment of endometriosis
Rižner, T. L., & Penning, T. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104446 · Cited by 55
Self-citationEnzymes as modulators in malignant transformation
Vihko, P., Herrala, A. M., Härkönen, P. K., ISOMAA, V. V., Kaija, H., Kurkela, R., Li, Y., Patrikainen, L., Pulkka, A. E., Soronen, P., et al. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.01.002 · Cited by 60
Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1
Brožič, P., Šmuc, T., Gobec, S., & Rižner, T. L. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.08.001 · Cited by 51
Adeniji, A. O., Uddin, M. J., Zang, T., Tamae, D., Wangtrakuldee, P., Marnett, L. J., & Penning, T. M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00160 · Cited by 47
Self-citationEffects of various pesticides on human 5α-reductase activity in prostate and LNCaP cells
Lo, S., King, I., Alléra, A., & Klingmüller, D. (2006) · Toxicology in Vitro · doi:10.1016/j.tiv.2006.10.016 · Cited by 61
Are primary cultures realistic models of prostate cancer?
Peehl, D. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10691 · Cited by 50
“In a study to determine whether AKR1C2 activity could be a source of 5adihydrotestosterone (the ligand that activates the androgen receptor in prostatic epithelial cells) in the prostate, my collaborators and I compared levels of AKR1C2 mRNA transcripts in primary cultures derived fromnormal tissues versus cancer [Riz…”
BackgroundSelf-citationYee, D. J., Balšánek, V., Bauman, D. R., Penning, T. M., & Sameš, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604672103 · Cited by 45
Self-citationAgapova, O. A., Kaufman, P. L., & Hernandez, M. R. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.10.021 · Cited by 47
Androgen biosynthesis in castration-resistant prostate cancer
Penning, T. M. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0109 · Cited by 54
“AKR1C3 catalyzes the NADPH-dependent reduction of D4-AD to testosterone, the reduction of Adione to DHT, and the reduction of androsterone to 3a-Adiol (Lin et al. 1997, Penning et al. 2000).”
InfluentialSelf-citationGunawan, A., Sahadevan, S., Neuhoff, C., Große‐Brinkhaus, C., Gad, A. Y., Frieden, L., Tesfaye, D., Tholen, E., Looft, C., Uddin, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063259 · Cited by 49
“[47].”
Zhang, A., Zhang, J., Plymate, S. R., & Mostaghel, E. A. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0250-9 · Cited by 48
“, catalyzing conversion of 3α-diol back to DHT), intracellularly it functions primarily to reduce DHT [3, 6].”
BackgroundJin, Y., & Penning, T. M. (2006) · Steroids · doi:10.1016/j.steroids.2005.12.002 · Cited by 37
Self-citationPromiscuity and diversity in 3-ketosteroid reductases
Penning, T. M., Chen, M., & Jin, Y. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.12.003 · Cited by 38
Self-citationNew agents and strategies for the hormonal treatment of castration-resistant prostate cancer
Sharifi, N. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.494178 · Cited by 35
“Reductive aldo-keto reductase 1C (AKR1C) enzymes, including AKR1C2 (also known as the type 3 3a-hydroxysteroid dehydrogenase), which is expressed in prostate cells, reduce the 3-keto of DHT to 5a-androstane-3a,17b-diol [61,72].”
BackgroundDiagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma
Zhu, P., Feng, R., Lu, X., Liao, Y., Du, Z., Zhai, W., & Chen, K. (2021) · Aging · doi:10.18632/aging.202380 · Cited by 34
“Aldo-keto reductases (AKRs) are NADP(H) oxidoreductases and catalyze reactions on a wide-ranging spectrum of substrates, including drugs and carcinogens [19, 20].”
BackgroundMiller, V. L., Lin, H.-K., Murugan, P., Fan, M. D., Penning, T. M., Brame, L. S., Yang, Q., & Fung, K.-M. A. (2012) · Europe PMC (PubMed Central) · Cited by 39
Self-citationWangtrakuldee, P., Adeniji, A. O., Zang, T., Duan, L., Khatri, B. B., Twenter, B. M., Estrada, M. A., Higgins, T. F., Winkler, J. D., & Penning, T. M. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.01.001 · Cited by 29
Self-citationSadgrove, N. J., Batra, S., Barreto, D., & Rapaport, J. A. (2023) · Cosmetics · doi:10.3390/cosmetics10040106 · Cited by 32
Zhang, B., Hu, X., Wang, X., Thériault, J.-F., Zhu, D., Shang, P., Labrie, F., & Lin, S. (2016) · Biochemical Journal · doi:10.1042/bcj20160083 · Cited by 27
Huang, K., Chiou, S., Chow, K., Lin, T., Chang, H., Chiang, I., & Lee, M. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03647.x · Cited by 25
“Rižner et al.(20) found that AKR1C2, which was highly expressed in prostatic cancer, was not detected in NTPE.”
BackgroundSulforaphane promotes murine hair growth by accelerating the degradation of dihydrotestosterone
Sasaki, M., Shinozaki, S., & Shimokado, K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.099 · Cited by 25
Parent, E. E., Carlson, K. E., & Katzenellenbogen, J. A. (2007) · The Journal of Organic Chemistry · doi:10.1021/jo070328b · Cited by 24
Papari-Zareei, M., Brandmaier, A., & Auchus, R. J. (2006) · Endocrinology · doi:10.1210/en.2005-1141 · Cited by 23
Intracrinology-revisited and prostate cancer
Penning, T. M., & Detlefsen, A. J. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105499 · Cited by 27
Self-citationTakahashi, R. H., Grigliatti, T. A., Reid, R. E., & Riggs, K. W. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.150995 · Cited by 21
“Based on its high expression in the prostate and its activity as a 3-ketosteroid reductase, AKR1C2 was identified as the major reductive enzyme responsible for catalyzing the biotransformation of DHT to 3 -diol (Rizner et al., 2003a).”
BackgroundAllopregnanolone: Metabolism, Mechanisms of Action, and Its Role in Cancer
Zamora-Sánchez, C. J., & Camacho‐Arroyo, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010560 · Cited by 18
Gorityala, S., Yang, S., Montano, M. M., & Xu, Y. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.05.008 · Cited by 18
Yang, Q., Titus, M. A., Fung, K., & Lin, H. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21731 · Cited by 18
“Both isozymes catalyze mainly 5a-DHT reduction for 3a-diol formation [Lin et al., 1997; Rizner et al., 2003].”
BackgroundResultInfluentialSelf-citationZhang, B., Zhu, D., Hu, X., Zhou, M., Shang, P., & Lin, S. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.01.003 · Cited by 19
A neuroactive steroid 5α‐androstane‐3α,17β‐diol regulates androgen receptor level in astrocytes
Agapova, O. A., Malone, P. E., & Hernandez, M. R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03879.x · Cited by 16
Xia, D., Lai, D. V., Wu, W., Webb, Z. D., Yang, Q., Zhao, L., Yu, Z., Thorpe, J. E., Disch, B. C., Ihnat, M. A., et al. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.11.006 · Cited by 17
Self-citation3α-Hydroxysteroid Dehydrogenase Type III Deficiency: A Novel Mechanism for Hirsutism
Steiner, A. Z., Chang, L., Ji, Q., Ookhtens, M., Stolz, A., Paulson, R. J., & Stanczyk, F. Z. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2708 · Cited by 15
Brožič, P., Cesar, J., Kovač, A., Davies, M., Johnson, A. P., Fishwick, C. W. G., Rižner, T. L., & Gobec, S. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.10.019 · Cited by 18
Zimmerman, R. A., Dozmorov, I. M., Nunlist, E., Tang, Y., Li, X., Cowan, R., Centola, M. B., Frank, M. B., Culkin, D. J., & Lin, H.-K. (2004) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500761 · Cited by 16
Self-citationAndo, T., Nishiyama, T., Takizawa, I., Ishizaki, F., Miyashiro, Y., Takeda, K., Hara, N., & Tomita, Y. (2016) · Scientific Reports · doi:10.1038/srep32198 · Cited by 17
Gerber, A., Milhim, M., Hartz, P., Zapp, J., & Bernhardt, R. (2016) · Metabolic Engineering · doi:10.1016/j.ymben.2016.02.010 · Cited by 14
Function, drug resistance and prognostic effect of AKR1C2 in human cancer
Wang, Z., Feng, Y., Song, J., Sun, D., & Zhang, Y. (2023) · Neoplasma · doi:10.4149/neo_2023_230206n66 · Cited by 13
Canonical and Noncanonical Androgen Metabolism and Activity
Storbeck, K., & Mostaghel, E. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_11 · Cited by 11
Watanabe, K., Kakefuda, A., Yasuda, M., Enjo, K., Kikuchi, A., Furutani, T., Naritomi, Y., Otsuka, Y., Okada, M., & Ohta, M. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.06.025 · Cited by 10
van Rooyen, D., du Toit, T., Toit, R. L.-D., Africander, D., Swart, P., & Swart, A. C. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.09.025 · Cited by 11
Effects of Testosterone on Benign and Malignant Conditions of the Prostate
Herati, A. S., Kohn, T. P., Butler, P. R., & Lipshultz, L. I. (2017) · Current Sexual Health Reports · doi:10.1007/s11930-017-0104-7 · Cited by 9
Rotinen, M., Villar, J., Celay, J., Serrano-Mendioroz, I., Notario, V., & Encío, I. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.03.015 · Cited by 10
Martins, A. G. G. D. M., Allegretta, G., Unteregger, G., Haupenthal, J., Eberhard, J., Hoffmann, M., van der Zee, J. A., Junker, K., Stöckle, M., Müller, R., et al. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.09.006 · Cited by 8
Wan, R., Kong, X., Yang, Y., Tao, S., Chen, Y., Teichmann, A. T., & Wieland, F. H. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105527 · Cited by 7
Mitsuizumi, H., & Mori, S. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c01751 · Cited by 6
Metadata
- Authors
- Rižner, T. L., Lin, H. K., Peehl, D. M., Steckelbroeck, S., Bauman, D. R., & Penning, T. M.
- Affiliations
- Department of Pharmacology, University of Pennsylvania School of Medicine (T.L.R., T.M.P., S.S., D.M.B.), Philadelphia, Pennsylvania 19104-6084
- University of Oklahoma Health Sciences Center (US)
- University of Pennsylvania (US)
- Stanford Medicine (US)
- Corresponding author
- Penning, Trevor M.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-07-01
- Volume
- 144
- Issue
- 7
- Pages
- 2922-2932
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2125072209
- Cited by
- 132
- References
- 33
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 3 · 2017: 5 · 2016: 10 · 2014: 10 · 2013: 10 · 2012: 3
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 97044)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK54925, DK-47015, R01DK054925, R01DK047015)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Keywords
- 3α-hydroxysteroid dehydrogenase, AKR1C2, aldo-keto reductase, androgen metabolism, dihydrotestosterone, 3α-androstanediol, 17β-hydroxysteroid dehydrogenase, androgen receptor activation, prostate cancer, PC-3 cells, LNCaP cells, glucuronidation
- MeSH terms
- Adenocarcinoma, Animals, Bone Neoplasms, Epithelial Cells, Humans, Hydroxysteroid Dehydrogenases, Isoenzymes, Male, Prostate, Prostatic Neoplasms, Dihydrotestosterone, Testosterone, Tumor Cells, Cultured, 17-Hydroxysteroid Dehydrogenases, Androstane-3,17-diol, Gene Expression Regulation, Enzymologic, COS Cells, 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific), In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.